209667-59-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Boc-4-ethoxycarbonylmethylpiperazine is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its ability to react with different functional groups allows for the creation of a wide range of medicinal compounds, contributing to the development of new treatments and therapies.
Used in Agrochemical Production:
In the agrochemical industry, 1-Boc-4-ethoxycarbonylmethylpiperazine serves as an intermediate in the production of various agrochemicals. Its versatility in organic chemistry facilitates the synthesis of compounds that can be used in crop protection and other agricultural applications.
Used in Organic Chemistry Research:
1-Boc-4-ethoxycarbonylmethylpiperazine is used as a building block in organic chemistry research for the development of new organic compounds. Its reactivity and the presence of the Boc protecting group make it a valuable tool for exploring novel chemical reactions and syntheses.
It is crucial to handle 1-Boc-4-ethoxycarbonylmethylpiperazine with care and adhere to proper safety protocols to mitigate any potential health and environmental risks associated with its use.

InChI:InChI=1/C13H24N2O4/c1-5-18-11(16)10-14-6-8-15(9-7-14)12(17)19-13(2,3)4/h5-10H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 40004-08-8 1-(Ethoxycarbonylmethyl)piperazine 
• 105-36-2 ethyl bromoacetate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 105-39-5 chloroacetic acid ethyl ester 
• 623-73-4 diazoacetic acid ethyl ester 
• 623-48-3 ethyl iodoacetae 

Downstream Products

• 40004-08-8 1-(Ethoxycarbonylmethyl)piperazine 
• 549506-81-2 (4-phenylmethanesulfonyl-piperazin-1-yl)-acetic acid 
• 156478-71-6 4-[(1,1-Dimethylethoxy)carbonyl]-1-piperazineacetic acid 
• 890281-18-2 C₁₄H₂₀N₂O₄S 
• 1305197-26-5 2-(4-benzenesulfonyl-piperazin-1-yl)-N-hydroxy-acetamide 
• 864442-44-4 ethyl 2-(4-benzoylpiperazin-1-yl)acetate 
• 1305197-77-6 C₁₆H₂₂N₂O₃ 
• 1305197-27-6 2-(4-benzenesulfonyl-piperazin-1-yl)-N-hydroxy-acetamide 
• 1305197-28-7 N-hydroxy-2-(4-phenylacetyl-piperazin-1-yl)-acetamide 
• 1338673-52-1 tert-butyl 4-(2-hydrazinyl-2-oxoethyl)piperazine-1-carboxylate 
• 77279-24-4 tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 
• 945953-41-3 4-(2-oxoethyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Ruthenium(III) chloride-catalyzed efficient protocol for ethyl diazoacetate insertion into the N-H bond of secondary amines

Ruthenium(III) chloride (1 mol%) alone can catalyze the insertion of ethyl diazoacetate into N-H bonds of various structurally and electronically diverse secondary cyclic amines under solvent-free conditions to afford the corresponding glycine esters in g

Fused ring compound, pharmaceutical composition containing fused ring compound, and preparation method and application of fused ring compound

The present invention relates to a fused ring compound as shown in Formula (I-A) or Formula (I-B) which is described in the specification, a pharmaceutical composition comprising the same, a preparation method and an application in the prevention or treatment of diseases or conditions associated with RET activity.

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo

Since the demonstration of nicotine vaccines as a possible therapeutic intervention for the effects of tobacco smoke, extensive effort has been made to enhance nicotine specific immunity. Linker modifications of nicotine haptens have been a focal point for improving the immunogenicity of nicotine, in which the evaluation of these modifications usually relies on in vivo animal models, such as mice, rats or nonhuman primates. Here, we present two in vitro screening strategies to estimate and predict the immunogenic potential of our newly designed nicotine haptens. One utilizes a competition enzyme-linked immunoabsorbent assay (ELISA) to profile the interactions of nicotine haptens or hapten-protein conjugates with nicotine specific antibodies, both polyclonal and monoclonal. Another relies on computational modeling of the interactions between haptens and amino acid residues near the conjugation site of the carrier protein to infer linker-carrier protein conjugation effect on antinicotine antibody response. Using these two in vitro methods, we ranked the haptens with different linkers for their potential as viable vaccine candidates. The ELISA-based hapten ranking was in an agreement with the results obtained by in vivo nicotine pharmacokinetic analysis. A correlation was found between the average binding affinity (IC50) of the haptens to an anti-Nic monoclonal antibody and the average brain nicotine concentration in the immunized mice. The computational modeling of hapten and carrier protein interactions helps exclude conjugates with strong linker-carrier conjugation effects and low in vivo efficacy. The simplicity of these in vitro screening strategies should facilitate the selection and development of more effective nicotine conjugate vaccines. In addition, these data highlight a previously under-appreciated contribution of linkers and hapten-protein conjugations to conjugate vaccine immunogenicity by virtue of their inclusion in the epitope that binds and activates B cells.

Synthesis, characterization, X-ray diffraction studies and biological evaluation of tert-butyl 4-(2-ethoxy-2-oxoethyl)-piperazine-1-carboxylate and tert-butyl 4-(2-hydrazino-2-oxoethyl)piperazine-1-carboxylate

Two derivatives of N-Boc piperazine, an ester derivative, i.e., tert-butyl 4-(2-ethoxy-2-oxoethyl)-piperazine-1-carboxylate (1), and, a hydrazide derivative tert-butyl 4-(2-hydrazino-2-oxoethyl)piperazine-1-carboxylate (2) were synthesized and were characterized by FT-IR, 1H & 13C NMR and LCMS spectroscopic studies. The structures of both 1 and 2 were further confirmed by single crystal X-ray diffraction analysis. The molecule of 1 is linear in shape with the ethyl acetate moiety adopting fully extended conformation, while the molecule of 2 is L-shaped with the molecule being twisted at the C10 atom. The crystal structure of 1 adopts a two-dimensional zig-zag architecture featuring C–H…O intermolecular interactions, while that of 2 features strong N–H…O hydrogen bonds and intermolecular interactions of the type N–H…N and C–H…N, resulting in a two-dimensional structure. Furthermore, a detailed analysis of the intermolecular interactions and crystal packing of 1 and 2 via Hirshfeld surface analysis and fingerprint plots was performed. The antibacterial and antifungal activities of both the compounds have been studied against several microorganisms, and were found to be moderately active.

METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF

Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.